Scholarlink

Background <p>While the prevalence of eosinophilic esophagitis (EoE) has increased, estimates of prevalence trends for non-esophageal eosinophilic gastrointestinal disease (EGIDs) are limited and costs associated with these conditions are unknown.</p> Aims <p>To estimate prevalence and healthcare costs for non-esophageal EGIDs in the U.S.</p> Methods <p>We analyzed two national health insurance claims databases, MarketScan (2009–2022) and Medicare (2009–2017), to calculate annual prevalence and healthcare cost for patients with ≥ 1 ICD-9/10 code for eosinophilic gastritis or gastroenteritis (EoG/EGE) or eosinophilic colitis (EoC). Estimates were age and sex-standardized to the 2020 U.S. Census data. Inflation adjusted costs included inpatient, outpatient, and pharmaceutical claims for the latest study year.</p> Results <p>Prevalence rates were 5.49/100,000 and 11.47/100,000 for EoG/EGE, and 1.95/100,000 and 7.91/100,000 for EoC, in MarketScan and Medicare, respectively. While overall prevalence increased modestly, EoC prevalence increased 2.7-fold in Medicare. Standardized to the U.S. population, prevalence was 6.6/100,000 for EoG/EGE and 3.0/100,000 for EoC, equal to 21,733 EoG/EGE and 9,944 EoC cases. The total healthcare costs were $2.08 million in 2022 for MarketScan and $3.87 million in 2017 for Medicare, mostly attributed to outpatient procedures. Extrapolated national one-year costs adjusted for 2022 inflation totaled $114 million.</p> Conclusions <p>For all non-esophageal EGIDs combined, there was a modest increase in prevalence over the last decade, yet non-esophageal EGIDs remained rare. Notably, EoC demonstrated a nearly three-fold increase among Medicare beneficiaries. Consistent with this finding, costs and burden of disease are highest among Medicare enrollees, suggesting older patients have more complex non-esophageal EGID healthcare needs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prevalence and Costs of Non-esophageal Eosinophilic Gastrointestinal Diseases in the United States

  • 期刊论文

  • 发表日期：

    2026年3月17日

查看全文
  • Stefani Aleman,
  • Chelsea Anderson,
  • Elizabeth T. Jensen,
  • Evan S. Dellon

摘要

Background

While the prevalence of eosinophilic esophagitis (EoE) has increased, estimates of prevalence trends for non-esophageal eosinophilic gastrointestinal disease (EGIDs) are limited and costs associated with these conditions are unknown.

Aims

To estimate prevalence and healthcare costs for non-esophageal EGIDs in the U.S.

Methods

We analyzed two national health insurance claims databases, MarketScan (2009–2022) and Medicare (2009–2017), to calculate annual prevalence and healthcare cost for patients with ≥ 1 ICD-9/10 code for eosinophilic gastritis or gastroenteritis (EoG/EGE) or eosinophilic colitis (EoC). Estimates were age and sex-standardized to the 2020 U.S. Census data. Inflation adjusted costs included inpatient, outpatient, and pharmaceutical claims for the latest study year.

Results

Prevalence rates were 5.49/100,000 and 11.47/100,000 for EoG/EGE, and 1.95/100,000 and 7.91/100,000 for EoC, in MarketScan and Medicare, respectively. While overall prevalence increased modestly, EoC prevalence increased 2.7-fold in Medicare. Standardized to the U.S. population, prevalence was 6.6/100,000 for EoG/EGE and 3.0/100,000 for EoC, equal to 21,733 EoG/EGE and 9,944 EoC cases. The total healthcare costs were $2.08 million in 2022 for MarketScan and $3.87 million in 2017 for Medicare, mostly attributed to outpatient procedures. Extrapolated national one-year costs adjusted for 2022 inflation totaled $114 million.

Conclusions

For all non-esophageal EGIDs combined, there was a modest increase in prevalence over the last decade, yet non-esophageal EGIDs remained rare. Notably, EoC demonstrated a nearly three-fold increase among Medicare beneficiaries. Consistent with this finding, costs and burden of disease are highest among Medicare enrollees, suggesting older patients have more complex non-esophageal EGID healthcare needs.